Patients with familial adenomatous polyposis (FAP) eventually develop colon cancer.
Colonic polyps of FAP patients display increased levels of meprin-A.
A meprin A targeted silicon-based drug delivery system was developed.
Sulindac and silymarin were used as therapeutic agents to prevent colon cancer.
The delivery system displayed preferential binding to colon cancer cells and tissue.